Prevalence and factors associated with the development of asthma in a cohort of children who were preterm infants and received passive immunization with palivizumab.
文献摘要
Objective To assess the prevalence of asthma in a cohort of preterm infants, comparing those who received prophylaxis with palivizumab, a monoclonal antibody against respiratory syncytial virus (RSV), with those who did not. That is relevant because RSV infection has been linked to recurrent wheezing and asthma in childhood, but a causal relationship remains unclear. Methods This was a prospective cohort study involving children who were preterm infants without congenital heart disease, exposed or not to palivizumab. Parents or legal guardians answered a telephone questionnaire adapted from the International Study of Asthma and Allergies in Childhood, which covers respiratory symptoms, allergy history, and potential risk factors. Results Among 292 eligible children, 217 were included (149 in the palivizumab group and 68 in the control group). Of those 217 infants, 25.3% (95% CI:19.9-31.5%) had asthma: 24.2% (95% CI: 17.8-31.5%) in the palivizumab group and 27.9% (95% CI: 18.3-39.5%) in the control group, with no significant difference (p = 0.553). In the bivariate analysis, asthma was significantly associated with a family history of atopy (p Conclusions Palivizumab does not seem to protect against asthma development in preterm infants without congenital heart disease. A family history of atopy, parental asthma, and allergic rhinitis in the child seem to be the primary determinants of asthma risk in such infants.